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Abstract
Introduction: The translational and predictive value of animal models highly depends on the validity of respective
readout parameters. In arthritis research, there has been a shift from sole threshold testing for pain-related
behavior, as well as from swelling and histology assessment for inflammation, toward an analysis of joint function
as indicated, for instance, by an increasing number of studies on gait abnormalities. Clinically, the range of motion
(ROM) of the affected joint plays a major role in diagnosis and the assessment of treatment benefits. This
parameter, however, is only insufficiently detected by currently used analytic systems in animals.
Methods: Here we used high-resolution videoradiographic analysis to assess ROM in experimental knee joint
arthritis in rats. This parameter is described during the 21-day course of antigen-induced arthritis in rats.
Furthermore, the therapeutic effects of antinociceptive (morphine) and anti-inflammatory (dexamethasone)
treatment on ROM are documented. To obtain additional information on the implications of ROM in animal
models, correlations were performed to measure pain-related behavior and inflammation.
Results: The study animals showed a significant reduction in ROM of the inflamed knee joint in the acute phase of
arthritis. This was accompanied by an increase in knee joint movement on the contralateral side, indicating a
compensational mechanism. Both morphine and dexamethasone treatment increased and thus normalized ROM.
Changes in ROM were further stage-dependently correlated with weight bearing and joint swelling, that is, with
both pain-related behavior and signs of inflammation.
Conclusions: The dynamic ROM observed in freely moving rats in our model of knee joint arthritis might serve as
a parameter for global disease activity and might thus represent a promising readout parameter for preclinical
assessment regarding the overall efficacy not only of antiarthritic but also of antinociceptive compounds.
Keywords: range of motion, rat, arthritis, mechanical thresholds, videoradiography, readout parameter, preclinical
testing
Introduction
Inflammatory processes in the joint are common, and a
large proportion of patients with chronic pain are in
fact arthritis patients [1]. While potent compounds exist
to alleviate arthritis-related symptoms, a large propor-
tion of patients remain insufficiently treated despite the
use of several different therapeutic regimens. Therefore,
there is a clear medical need for the development of
novel antirheumatic and antinociceptive compounds.
One major problem in preclinical arthritis research is
a reliable assessment of symptom severity and its allevia-
tion by standard of care medication in respective animal
models to achieve a good translational potency for pre-
dicting clinical outcome. In recent years, it has become
more and more obvious that in addition to, for instance,
pain threshold detection or assessment of joint swelling
[2], functional parameters have great potential to iden-
tify arthritis-related surrogate parameters in animals. In
this respect, readout systems have been developed that
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tion induced in one or more joints. Parameters assessed
include the speed of walking, spatial and temporal mea-
sures of step cycles (distances between pawprints, stance
time, swing time and so on), the pressure and area of
the pawprints and rotation in the respective limb [3-8].
One parameter which is of great clinical importance in
a r t h r i t i sp a t i e n t si st h er a n g eo fm o t i o n( R O M )i nt h e
respective joint. This measure, describing the maximum
flexion and extension movements in a joint from a neu-
tral angle used for primary assessment, for describing
the disease course and for estimating the efficacy of
treatment. ROM measurements can be obtained at rest
(static) or during movement by using videography
(dynamic) [9-11]. In humans with knee joint arthritis,
the respective ROM has been shown to be reduced
[12,13], and this reduction furthermore correlates with
the overall physical ability of patients [9]. To our knowl-
edge, such a parameter in a respective animal model has
not yet been described. Therefore, we aimed to quantify
the working range of an inflamed knee joint in the
model of antigen-induced arthritis (AIA) in rats and to
compare this measurement to that of healthy animals.
Similarly to kinematic examination in humans, we did
not artificially move the joint until the animals vocalized
or withdrew, but instead quantified the maximal and
minimal angles between the femur and tibia in a freely
moving animal (dynamic ROM). For that purpose, ani-
mals were left walking through a tunnel, and high-speed
X-ray cameras filmed the movement of the skeleton at
high resolution (500 frames/second). By using this
method, we captured the respective angles using frame-
by-frame analysis.
AIA was chosen as an immune-mediated joint inflam-
mation whose histopathology shows many similarities to
human rheumatoid arthritis [14,15]. For experimenta-
tion, the AIA model has several advantages. In immu-
nized rats, only the AIA joint develops inflammation,
thereby enabling the examination of contralateral com-
pensational effects. Furthermore, AIA has an incidence
of 100%, its acute phase starts within the first hours
after antigen injection into the joint and it sponta-
neously progresses into chronic mononuclear inflamma-
tion with a homogeneous time course [14-17].
In addition to gaining information on the time course
of this measure during the course of AIA, we aimed to
distinguish between the influences of pain and mechani-
cal factors such as swelling and joint destruction on this
parameter. Hence, we included AIA animals treated
with either morphine for alleviating pain or with dexa-
methasone as a standard anti-inflammatory agent.
Furthermore, measures of primary and secondary hyper-
algesia as assessed using mechanical and thermal thresh-
old testing and measures of inflammation-induced
weight shifting were obtained and correlated to the
ROM.
Materials and methods
Induction of antigen-induced arthritis
Forty female Lewis rats (ages 6 to 8 weeks old and
weighing 160 to 180 grams; Charles River, Sulzfeld, Ger-
many) were used for the studies. AIA was induced as
reported previously [15,17]. For immunization, 500 μg
of antigen (methylated bovine serum albumin (mBSA);
Sigma, Deisenhofen, Germany) in saline emulsified with
500 μLo fF r e u n d ’s complete adjuvant (Sigma) supple-
mented with 2 mg/mL Mycobacterium tuberculosis
strain H37RA (Difco, Detroit, MI, USA) were injected
subcutaneously twice with a one-week interval between
immunizations. After another two weeks, a sterile mBSA
solution (500 μgi n5 0μL) was injected into the left
knee joint cavity to induce monoarticular AIA in 30
rats. The results obtained from these animals were com-
pared with those obtained from the remaining 10 rats,
in which the latter intraarticular injection was omitted.
These animals are referred to as “controls” below. All
experiments were approved by the Thuringian state
authorities (registration number 02-039/08) and com-
plied with EC regulations (86/609/EEC) for the care and
use of laboratory animals. The Extended Methods Form
(EMF) for uniform reporting standards [18] can be
found in Additional file 1.
Treatment protocol and groups
Of the 30 rats in which AIA was induced, 10 were trea-
ted with morphine (Sigma) at a dose of 2.5 mg/kg in a
volume of 250 μL intraperitoneally every testing day 30
minutes prior to behavioral testing. This dose lies in the
range of morphine applications usually used for locomo-
tor assessment in arthritic animals [19]. Another group
of 10 animals were treated with dexamethasone (Forte-
cortin Inject; Merck Pharma, Darmstadt, Germany)
starting six hours after induction of AIA and received
daily injections of 0.3 mg/kg diluted in 300 μLo na
five-day injection/two-day no injection schedule to avoid
dramatic weight loss (treatment regime adapted from
[20]). Following the same treatment scheme as the one
we used for dexamethasone, the remaining 10 AIA ani-
mals were treated with saline (0.9% NaCl). All animals
were assessed for behavioral measures and locomotion
twice before induction of arthritis and on days 1, 3, 7,
14 and 21 after induction of AIA.
Videoradiography
On each testing day, animals were left spontaneously
walking in a Plexiglas tunnel 2 m in length (height and
width 150 mm each). The tunnel was darkened at one
end, where the animals went following their instinct to
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when the animals walked with constant speed, radio-
graphs were obtained in a lateral perspective using a
digital high-speed X-ray system (Neurostar; Siemens,
Erlangen, Germany). For the experimental setup used,
see Figure 1. Radiographs were recorded with a sam-
pling rate of 500 Hz and a resolution of 1,536 × 1,024
pixels from the amplifier using a high-speed camera
(SpeedCam Visario G2; Weinberger Vision GmbH,
Erlangen, Germany). For each animal and each testing
day, four runs were recorded, corresponding to approxi-
mately eight complete step cycles.
On the X-ray films, the coordinates of defined joint and
bone structures were tracked at least in every tenth frame
using Simi Motion 3D (Simi Reality Motion Systems
GmbH, Unterschleissheim, Germany). The coordinates in
the remaining frames were then completed via extrapola-
tion. In particular, the following landmarks were defined:
point 1 was the center of the proximal femoral epiphysis
at the level of the femoral neck, point 2 was the center of
the distal femoral epiphysis at the level of the epicondylus,
point 3 was the center of the proximal tibial epiphysis and
point 4 was the center of the distal tibial epiphysis at the
level of the ankle (Figure 2). Using these landmarks, we
calculated the longitudinal axes of the femur and tibia for
each frame. The knee joint angle was calculated as the
posterior angle between the two bone axes (Figure 2).
The ROM in the knee joint was then obtained from
the maximum and minimum joint angles for a complete
step cycle as well as separately for stance and swing
phases (for further explanation, see Figure 3).
Pain-related behavior
Primary hyperalgesia at the site of the inflamed knee was
assessed using a dynamometer (Correx, Bern, Switzerland)
[21]. Increasing pressure was applied to the lateral side of
the knee joint at the level of the joint space until the ani-
mals attempted to escape or vocalized as described pre-
viously [4,22]. The weight force applied to elicit this
response was read out in grams. For each animal and each
testing day, this test was performed once, since repeated
testing might further sensitize the nociceptive apparatus. To
prevent tissue damage, a cutoff value of 250 g was defined.
Pain-related guarding behavior of the inflamed hind-
paw was assessed by quantification of weight bearing
toward the noninflamed hindlimb using an incapaci-
tance tester (Linton Instrumentation, Norfolk, UK).
Here animals were placed into a plastic cage with both
hindpaws resting on scales. After acclimation to the
device when the animal was sitting calmly, the weight
force resting on the two scales was obtained and aver-
aged during a 3-second interval, and values from three
consecutive measurements were averaged for every test-
ing day. From these values, the relative weight
(expressed as percentages) resting on the inflamed hin-
dlimb was calculated (weight on inflamed hindlimb ×
100% ? (weight on inflamed hindlimb + weight on non-
inflamed hindlimb)) as described previously [23,24].
In addition, a guarding score was assessed as described
previously [17]: 0 was defined as no guarding; 1 was
defined as guarding of the hindlimb after a defined
brief, noxious compression of the knee; 2 was defined as
visible limping during walking without previous pain sti-
mulus; 3 was defined as no use of the hindlimb with the
arthritic knee; and 4 was defined as no movement at all
(general morbidity).
Histology and grading of arthritis
Swelling was assessed by measuring the mediolateral
diameter of each knee using a vernier caliper (Mitutoyo,
Figure 1 (A) Sketch of the experimental setup of the X-ray device. The arrow indicates the direction in which the rat moves while it is
filmed by a high-speed camera and X-ray videoradiographs are taken in the lateral and dorsoventral directions. Range of motion was measured
using the lateral direction recordings. (B) A photograph of the setting is presented for clarity.
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the relative swelling was calculated by subtracting the
diameter of the noninflamed knee from that of the
inflamed knee, thus controlling for anatomical knee
joint differences between animals.
The histology of the knee joints was assessed on day 21.
Rats were deeply anesthetized with 120 mg/kg sodium
thiopentone intraperitoneally (Trapanal; Byk Gulden, Kon-
stanz, Germany) and perfused with heparin-enriched PBS
and 4.0% phosphate-buffered formalin. The knee joints
were removed, skinned, postfixed in formalin, decalcified
in 7% AlCl3 ( i n2 . 1 %H C la n d6 %f o r m i ca c i d )f o r4 8
hours, embedded in paraffin, cut into 5-μm-thick frontal
sections and stained with hematoxylin and eosin. Two
independent observers unaware of the treatment scored
the sections (0: no alteration, 1: mild alteration, 2: moder-
ate alteration and 3: severe alteration) for the following
alterations: (1) the amount of fibrin exudation and the rela-
tive number and density of granulocytes in the synovial
membrane and joint space allowed grading of the acute
inflammatory reaction; and (2) the relative number and
density of infiltrating mononuclear leukocytes in the syno-
vial membrane, the degree of synovial hyperplasia and the
extent of infiltration and fibrosis in the periarticular struc-
tures allowed grading of chronic inflammation. The scores
reflect the sum of all single values for the different criteria.
Cartilage and bone destruction were also scored (0: no ero-
sion, 0.5: erosion <10%, focal, 1: 10% to 20%, 1.5: >20% to
40%, 2: >40% to 60%, 2.5: >60% to 80%, and 3: >80%
destruction of cartilage and bone in cross-sections) [17,25].
Statistical analyses
SPSS for Windows version 17.0 software (SPSS, Inc.,
Chicago, IL, USA) was used for statistical analyses. Data
were tested for normal distribution by applying Kolmo-
gorov-Smirnov tests. All parameters except histopatho-
logical scores showed normal distribution. For
comparison between groups, repeated-measures
ANOVA was performed with the between-subjects fac-
tor Group (controls versus saline-, morphine- and dexa-
methasone-treated AIA) and the within-subjects factor
Time (baseline and days 1, 3, 7, 14 and 21 after induc-
tion of AIA). Post hoc t-tests were used to describe dif-
ferences between groups at different time points
whenever ANOVA revealed a significant Group × Time
interaction.
Histopathological scores for chronic inflammation and
joint destruction were compared between saline, mor-
phine and dexamethasone treatments by using nonpara-
metric Mann-Whitney U tests and applying the
Bonferroni-Holm correction to account for multiple
comparisons.
Kinematic parameters assessed on the basis of videora-
d i o g r a p h yw e r ec o r r e l a t e dw ith parameters indicating
pain-related behavior (primary mechanical hyperalgesia
and secondary thermal hyperalgesia) and with factors
indicating mechanical disturbance of gait (histopatholo-
gical scores for inflammation and bone and/or cartilage
destruction, knee swelling) using nonparametric Spear-
man correlation analyses. Significance was accepted at P
< 0.05.
Results
All 30 animals in which intraarticular mBSA injections
were performed developed signs of AIA, including swel-
ling, pain-related behavior and histopathological changes
assessed on day 21, and therefore they were included in
the analysis.
Figure 2 Landmarks of the rat skeleton used for the determination of the knee joint angle. Point 1 is the center of the proximal femur
epiphysis at the level of the femur neck, point 2 is the center of the distal femur epiphysis at the level of the epicondylus (with points 1 and 2
defining the femoral axis), point 3 is the center of the proximal tibial epiphysis and point 4 is the center of the distal tibial epiphysis at the level
of the ankle (with points 3 and 4 defining the tibial axis). The knee joint angle was calculated on the posterior side between the two axes
(Angle).
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In nonarthritic control animals, videoradiographic analy-
sis revealed a knee joint angle of approximately 60° at
t h ee n do ft h es w i n gp h a s e( s e eF i g u r e3 A ) .A f t e rb r i e f
flexion, the angle increased to approximately 100° (knee
joint extension) when the hindlimb was lifted off the
ground (end of stance phase, beginning of swing phase).
Following this, the knee joint was flexed to 40° before
increasing to 60° for touchdown (see Figure 3A). The
mean ROM in this joint, defined as the difference
between the maximum and minimum angles, was
approximately 60° (see example in Figure 3A). In con-
trast, arthritic rats that did not use their inflamed hin-
dlimbs (see example in Figure 3A) did not show major
movement in the knee joint, but held it at a rather con-
stant angle of around 50° during the complete walking
cycle, which cannot be divided into stance and swing
phases in these animals, since there is no contact with
the floor at any time.
In nonarthritic animals, the ROM remained around
baseline values during the complete observation period
of 21 days (Figure 3B). However, in arthritic animals,
the ROM in the arthritic joint was dramatically reduced
in the acute phase of arthritis and slowly recovered to
the levels of nonarthritic controls between days 7 and
14 after induction of arthritis (Figure 3B). To maintain
locomotion, this diminished movement is compensated
by an increased ROM in the contralateral knee joint
which mirrors the curve of the ipsilateral joint over time
(Figure 3B). Hence, this increased movement appears to
be compensational counterregulation of locomotion due
to arthritis-induced gait disturbance. This view is further
supported by correlational data between the ipsilateral
and contralateral knee joints when correlated across all
animals (Figure 3C), which shows the data to be
significant.
Effects of anti-inflammatory and antinociceptive
treatment on locomotion
A significant Group × Time interaction could be
observed for the guarding score [F(15,86) = 3.798; P <
0.001]. In particular, AIA animals treated with saline
showed visible limping up to the end of the observation
period on day 21, while morphine attenuated this sign
at all observed time points. Dexamethasone treatment
clearly reduced the inflammation-associated locomotor
dysfunction in the acute phase (days 1 and 3 after
i n d u c t i o n )a n dc o m p l e t e l yn o r m a l i z e di tf r o md a y7
(Figure 4A).
Of the parameters obtained from videoradiography,
the ROM of both the inflamed joint [F(15,86) = 1.895; P
= 0.035] and the contralateral, noninflamed knee joint
[F(15,83) = 2.182; P =0 . 0 1 3 ]s h o w e das i g n i f i c a n t
Group × Time interaction (Figures 4B and 4C). This
Figure 3 Locomotion in healthy and arthritic rats. (A) Knee joint
angles (y-axis) during a complete walking cycle from one
representative control animal (filled circles) and from one
representative arthritic animal on day 3 after induction of arthritis
which did not use the inflamed hindlimb at all (open circles). In the
latter animal, the range of motion, defined as the difference
between the maximum and minimum knee joint angles during one
gait cycle, is reduced. (B) Range of motion in the inflamed and the
contralateral noninflamed knee joint during the time course of
antigen-induced arthritis (AIA) (circles) and in both knee joints of
nonarthritic controls during the 21-day observation period (squares).
BL : baseline. (C) Correlation of range of motion between inflamed
and noninflamed knee joints. Each filled circle represents data from
a single animal. ROM: range of motion.
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(F = 1.889 and P = 0.041, F = 2.120 and P =0 . 0 1 6 ,
respectively), but only for the contralateral knee joint in
the swing phase (F = 1.528 and P = 0.122, F = 1.994
and P = 0.025, respectively).
While noninflamed control animals showed a sym-
metric gait (Figure 5A and Additional file 2), rats trea-
ted with saline showed a pronounced change in their
overall gait, mainly due to a diminished use of the
inflamed hindlimb which was either not used at all for
locomotion or was used for very little support only.
Representative sequences are shown in Figure 5B (also
see Additional file 2). Morphine, and to an even higher
degree dexamethasone treatment, partially normalized
these alterations (Figures 5C and 5D and Additional
file 2).
In the very acute phase, the ROM in the inflamed
joint of the saline-treated animals significantly decreased
(Figure 6B) in comparison to controls (Figure 6A), while
again morphine (Figure 6C) and dexamethasone (Figure
6D) attenuated the inflammation-related reduction in
the working range of the joint.
When monitoring the ROM of the inflamed and the
noninflamed knee joints over time, we observed that sal-
ine-treated animals, as compared to controls, showed
the most pronounced decrease in the acute phase,
slowly recovering up to day 21 (Figures 4B and 4C).
Furthermore, a strong compensational increase of move-
ment was obvious on the contralateral side (Figures 4B
and 4C; also see Figure 5 and Additional file 2). Inter-
estingly, the decrease on the ipsilateral side was attenu-
ated by morphine in the acute phase only and to a
greater degree by dexamethasone in the chronic phase
(Figure 4B), while the compensational movement on the
contralateral side appeared to be relatively independent
of the underlying treatment, except for the smaller
values in the very acute phase on day 1 (Figure 4C).
Effects of morphine and dexamethasone treatment on
pain-related behavior
Significant Group × Time interactions could be
observed for primary mechanical hyperalgesia [F(15,86)
= 4.304; P < 0.001] and weight bearing [F(15,86) =
2.863; P < 0.001], but not for secondary hyperalgesia
assessed on the contralateral knee [F(15,86) = 1.615; P =
0.086].
In particular, weight forces to elicit withdrawal at the
site of the inflamed knee joint were dramatically
reduced in saline-treated animals and could nearly be
prevented by morphine treatment. Dexamethasone did
not have a strong antinociceptive effect in the acute
phase of AIA, but tended to normalize mechanical
thresholds from day 7 after induction of arthritis (Fig-
ure 7A).
Figure 4 Locomotor parameters in the different treatment
groups over time. (A) Limping score. (B) Range of motion (ROM)
in the inflamed ipsilateral knee joint. (C) ROM in the noninflamed
contralateral knee joint. Data are presented as means ± SEM.
*Differences between saline and dexamethasone. §Differences
between saline and morphine. +Differences between morphine and
dexamethasone. Differences between immunized controls and the
treatment groups are not presented. *P < 0.05; **P < 0.01; ***P <
0.001. AIA: antigen-induced arthritis.
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paw was again most prominent in saline-treated animals,
only gradually normalizing until day 21. Here morphine
and dexamethasone showed a similar effect, with an
attenuated shift in the acute phase and a faster normali-
zation toward baseline values (Figure 7B).
Effects of morphine and dexamethasone treatment on
inflammation and joint destruction
A significant Group × Time interaction was observed
for joint swelling [F(15,86) = 6.734; P < 0.001]. Here
dexamethasone potently reduced joint swelling, comple-
tely abolishing it from day 7 after induction of AIA,
while morphine treatment was not different from saline
application (Figure 8A).
End point analysis using histopathology revealed no
signs of acute inflammation in any of the animals (a sin-
gle score of 1 was reported in one animal in the saline-
treated group) and no difference between treatment
groups. Regarding histopathological signs of chronic
inflammation, a significant anti-inflammatory effect was
apparent for dexamethasone treatment (P = 0.009 versus
morphine and P = 0.019 versus saline), while morphine
was again comparable to saline with respect to inflam-
mation (Figure 8B). Joint destruction was likewise
reduced in the dexamethasone-treated animals (P =
0.031 versus morphine and P = 0.047 versus saline) (Fig-
ure 8C).
Correlation analyses
The most stable correlation during the observation per-
iod was obtained between ROM on the contralateral
side and the guarding score (day 1: r = 0.736, P = 0.015;
day 3: r =0 . 7 1 5 ,P =0 . 0 2 0 ;d a y7 :r = 0.699, P = 0.024;
day 14: r =0 . 6 4 1 ,P = 0.041), indicating that this rather
subjective score mainly represents a compensational
gain of movement in the contralateral knee. ROM on
the inflamed side significantly correlated with weight
bearing as assessed using an incapacitance tester in the
early phase (day 1: r = 0.642, P = 0.045; day 7: r =
0.656, P = 0.039). In the later stages, ROM in the
inflamed knee correlated with joint swelling (day 7: r =
-0.831, P = 0.006; day 14: r =- 0 . 7 3 9 ,P = 0.015; day 21:
r = -0.667; P = 0.035). No further correlations were
obtained, and in particular, ROM parameters did not
correlate with pain threshold parameters at any stage of
arthritis.
Discussion
In this study, we employed videoradiographic analysis
for the first time to describe the ROM in inflamed and
noninflamed knee joints of freely moving rats and to
relate these data to the inflammatory process and to
inflammation-associated pain. The following are the
main results that we found. First, in the inflamed knee
joint, ROM was dramatically reduced at the acute stage
of AIA and slowly recovered to baseline values during
the observation period of 21 days. Second, ROM in the
inflamed knee was improved by both the anti-inflamma-
tory treatment with dexamethasone (throughout the
course of AIA) and the antinociceptive treatment with
morphine (at the early stage of AIA), indicating that
changes in ROM reflect both inflammation and pain in
a stage-dependent manner. Third, correlational analyses
showed an association between ROM in the inflamed
joint and weight bearing (a parameter of spontaneous or
load-dependent pain) in the acute phase, as well as an
association between ROM and joint swelling (indicating
arthritis severity) in the more chronic stages. Overall,
we thus propose that the reduction of ROM in the
Figure 5 Walking sequences of representative animals from each treatment group on day 1 after induction of AIA depicting different
phases of the gait cycle. (A) Immunized control, no AIA. (B) AIA, saline treatment (C) AIA, morphine-treatment. (D) AIA, dexamethasone
treatment. AIA: anitigen-induced arthritis.
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severity of arthritis in experimental arthritis models
rather than a solely pain-related, inflammation- or joint
destruction-related parameter. Fourth, in the contralat-
eral healthy knee joint, ROM was significantly increased,
thus compensating for the loss of movement in the
inflamed joint.
The examination of knee joint ROM adds a new
dimension to the previously used methods of gait analy-
sis in pain and arthritis research. While to date studies
have mainly employed temporal or spatial parameters of
gait, such as walking speed [5,6,26], duration of stance
and swing phases [27,28] and distances or angles
between pawprints or footprint pressure [4,19], we have
introduced a functional measure of movement which
cannot be detected by the methods described previously.
This is of particular importance with regard to severe
arthritis-related gait changes. As described previously,
some animals do not utilize their inflamed hindlimbs,
thereby making an assessment based on pawprints, such
as pawprint stains or the CatWalk method, impossible
[4,8]. In previous studies, data from these most severely
affected animals were partly removed from the study,
since no objective gait measures could be obtained in
early stages of experimental arthritis [4,17].
The relation of ROM parameters to spatial and tem-
poral measures might add to the understanding of dis-
ease-related guarding in the future, such as which
change in joint movement leads to which gross gait
abnormality. It is further worth mentioning that the
Figure 6 Change of knee joint angle in the inflamed ipsilateral knee joint during a complete walking cycle measured in
representative animals from each treatment group. (A) Immunized control, no AIA. ROM is defined as the difference (in degrees) between
the maximum and minimum knee joint angles reached during a complete step cycle. (B) AIA, saline treatment. (C) AIA, morphine treatment. (D)
AIA, dexamethasone treatment. AIA: antigen-induced arthritis; ROM: range of motion.
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between species [29,30]. In our study, healthy rats dis-
played ROM values of approximately 60°, a finding
which has also been described in studies involving
healthy humans [9,13,31]. Knee joint pathology has been
shown to reduce this ROM to 15° to 36° in rheumatoid
arthritis and to 33° to 40° in osteoarthritis [31], depend-
ing on disease severity. Therefore, the results presented
here might be transferable to human disease states.
On the basis of the experiments presented here, we can-
not determine the exact underlying causes of the decrease
in joint movement, since this is related to both joint
swelling and measures of pain-related behavior. In pre-
vious studies in humans with rheumatoid arthritis or knee
joint osteoarthritis, decreased ROM in arthritic joints has
also been described [9,10,12,13,32]. In these studies, parti-
cular associations have been found between reduced ROM
a n dm u s c l es t r e n g t h[ 3 3 ]a n dj o i n tl o a d[ 1 3 ] ,a sw e l la s
with Health Assessment Questionnaire scores [9], which
reflect disease activity, including muscle strength [34] and
pain to a significant degree [35]. Furthermore, associations
of knee joint function with joint stiffness and radiographi-
cally assessed joint destruction have been suggested
[31,36]. In our experiments, dexamethasone-treated ani-
mals showed significantly reduced joint swelling and
hardly any histopathological signs of chronic inflammation
or cartilage and bone destruction, whereas pain-related
behavior was still obvious. On the other hand, morphine
was capable of significantly attenuating pain-related
Figure 7 Pain-related behavior in the different treatment
groups over time. (A) Primary mechanical hyperalgesia obtained
from mechanical thresholds at the inflamed knee joint. (B) Weight-
bearing of arthritic animals as indicated by the relative body weight
resting on the inflamed hindlimb. Data are presented as means ±
SEM. *Differences between saline and dexamethasone. §Differences
between saline and morphine. +Differences between morphine and
dexamethasone. *P < 0.05; **P < 0.01; ***P < 0.001. AIA: antigen-
induced arthritis.
Figure 8 Severity of inflammation in the different treatment
groups. (A) Joint swelling displayed as delta (Δ) between ipsilateral
(inflamed) and contralateral (noninflamed) knee joints during the
observation period of 21 days. *Differences between saline and
dexamethasone. +Differences between morphine and
dexamethasone. (B) Histopathological scores of joint inflammation.
(C) Histopathological scores of cartilage and bone destruction. Data
are presented as means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
AIA: antigen-induced arthritis.
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meters. Therefore, the ROM in the knee joint is unlikely
to represent a parameter for inflammation or pain alone,
but rather for global arthritis-related disability.
Regardless of the severity of arthritis in the inflamed
joint or pharmacological treatment, we observed dra-
matic counterregulation in the contralateral hindlimb to
maintain progression. This was reflected in a signifi-
cantly increased ROM in these joints. With regard to
the respective movement of the affected animals (also
see Additional file 2), this finding is due to an increased
strain on the contralateral hindlimb to guarantee loco-
motion. In the most extreme cases, when animals do
not use their inflamed hindlimbs at all, the distance to
be crossed is overcome by jumping movements of the
noninflamed side. Even when the hindlimb is slightly
u s e d ,h o w e v e r ,t h en o n i n f l a m e dl i m bi su s e dt op u s h
the body farther away from the surface than in healthy
controls, thereby guarding the inflamed limb and
decreasing the stance time of the latter.
A somewhat trivial, yet interesting, aspect of this study is
the finding that the guarding score which is used to
describe the limping and guarding of arthritic animals cor-
related with ROM on the contralateral side for nearly the
complete observation period, but not with ROM in the
inflamed knee. This makes sense, since a gain of function
is usually easier to observe than a loss of function. There-
fore, when subjectively quantifying limping in animals,
observers have apparently detected the compensation in
the noninflamed joint rather than the actual impairment
in the affected knee. This might also be of putative clinical
importance, since such compensational movements which
outrange the normal functional working parameters of the
joint might explain symptoms in neighboring and/or con-
tralateral joints, which are commonly described in both
human and animal models (secondary hyperalgesia).
All findings regarding the contralateral hindlimb and
thus the assessment of counterregulation could be
obtained mainly because we used an asymmetric unilat-
eral inflammation model, namely, AIA. Since only one
knee joint is affected in this model, the contralateral joint
serves as an internal control. Furthermore, changes in
corresponding joints on the other side of the body can be
analyzed regarding putative compensational mechanisms.
In symmetric models such as adjuvant-induced arthritis
or collagen-induced arthritis, compensation is not possi-
ble and changes can only be related to healthy controls.
Overall, the ROM observed in both knee joints pro-
vides a good screening tool for the estimation of global
disease severity in animal models of experimental arthri-
tis and might thus be valuable as an outcome parameter
in preclinical assessment of novel antirheumatic or anti-
nociceptive compounds. Particularly in the early phase of
arthritis, up to day 3 of AIA, the antinociceptive
component can be examined, while over the complete
observation period, an estimation of antiarthritic efficacy
can be made. Here we validated the respective readout
parameters for the model of AIA using anti-inflammatory
and antinociceptive pharmacological interventions.
Whether these data are unequivocally transferable to
other commonly used experimental arthritis models is
subject to more detailed analysis in such animals.
Conclusions
On the basis of the data presented here, pharmacological
interventions selectively targeting pain or inflammation
discriminate well between groups, whereas the ROM in
the inflamed joint is improved to a similar degree by
both treatments. Thus, this measure does not represent a
solely pain-related, inflammation-related or joint destruc-
tion-related parameter. However, the reduction in ROM
of the inflamed knee joint represents a valuable para-
meter to use in the assessment of the global severity of
arthritis in experimental arthritis models and appears to
be well transferable to human disease states, thereby
making it a promising readout parameter for the preclini-
cal assessment of anti-inflammatory agents.
Additional material
Additional file 1: The Extended Methods Form (EMF) for uniform
reporting standards.
Additional file 2: Radiographic and high-resolution movies showing
representative animals from the different treatment groups.
Depicted are an immunized control animal (no arthritis) displaying
normal locomotion; an animal with antigen-induced arthritis (AIA)
treated with saline displaying very obvious limping, not using the
affected hindlimb at all; an animal with AIA and morphine treatment,
which guards the affected hindlimb, yet uses it for moving; and an
animal with AIA and dexamethasone treatment displaying a pattern
similar to that of the morphine-treated animal.
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